SpaceFund, based in Houston and Austin, has almost reached halfway for its $20 million fundraise. Photo via NASA/Unsplash

A venture capital firm co-located in Houston and Austin has announced a recent closing of a $20 million fund.

SpaceFund has raised $9 million toward its its $20 million BlastOff Fund as of this week — surpassing its initial first close goal of $5 million.

"We are thrilled to see how many investors are placing their trust in our team," says SpaceFund founder Rick Tumlinson in a news release. "We spent a lot of time slowly and carefully developing our processes and credibility, so we can better serve both investors and the amazing space startup community, and it's paying off."

Launched in 2019 with an initial fund that closed in August of 2020, SpaceFund has already invested in 13 exciting space startups. The new fund will build on those investments while also expanding its portfolio, according to the release.

"SpaceFund is about combining a bold approach with a very conservative diligence and investment process," says Meagan Crawford, SpaceFund's managing partner, in the release. "The BlastOff Fund continues our careful growth plan but is designed to accelerate our ability to place investment into those companies that are leading the Space Revolution."

San Francisco-based innovator Jed McCaleb — co-founder and the CTO of Stellar Development Foundation, a nonprofit building an accessible cryptocurrency platform — anchored the BlastOff Fund.

"I came to SpaceFund to ask questions because they are seen as credible thought leaders in the space investment industry," McCaleb says in the release. "By the time we finished talking, it was clear they were an obvious choice to help me invest in this amazing field."

McCaleb has a keen interest in commercial space, according to the release.

"Jed is a well-informed investor and one who deeply cares about the future of space and humanity," adds Crawford. "He is exactly the kind of investor we hope to attract into the SpaceFund family. For us, this isn't just about money. It is about how we can best impact the future. Jed and the other investors in the fund get that."

Houston-based space companies Axiom Space, Eden Grow Systems, and Cognitive Space are among SpaceFund's current portfolio.

"There is a reason we call this the BlastOff fund," says Tumlinson. "Anyone who follows what is happening in space can see that after almost 60 years, this industry is taking off. Our job is to help investors climb aboard the right companies to carry them to their financial destinations as we open the Frontier."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”